呼吸器外科(2)

研究成果

年別の研究成果 2000 2017 2018 2019 2023

• 241 学術誌
• 19 総説
• 3 コメント/討論
• 2 レター

年別の研究成果

年別の研究成果

検索結果

• 2023

  Conservative treatment for residual lung congestion after left upper trisegmentectomy: a case report

  Nagano, T., Haratake, N., Matsudo, K., Hashinokuchi, A., Watanabe, K., Takamori, S., Kohno, M., Miura, N., Takenaka, T. & Yoshizumi, T., 2月 2023, In: Translational Cancer Research. 12, 2, p. 421-426 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Case Report 100%
  • Conservative Treatment 100%
  • Lung Congestion 100%
  • Surgery 75%
  • Patient 50%

• Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?

  Kyushu University Lung Surgery Study Group, 2023, (印刷中) In: Thoracic Cancer.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

• Mediastinal synovial sarcoma invading the right inferior pulmonary vein and left atrium

  Nagano, T., Takenaka, T., Ono, Y., Kohno, M., Shiose, A. & Yoshizumi, T., 2023, (印刷中) In: JTCVS Techniques.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

• Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma

  Kinoshita, F., Shimokawa, M., Takenaka, T., Okamoto, T., Taguchi, K., Oda, Y. & Yoshizumi, T., 2023, (印刷中) In: Thoracic Cancer.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access
• 2021

  Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors

  Takamori, S., Takada, K., Shimokawa, M., Matsubara, T., Fujishita, T., Ito, K., Toyozawa, R., Yamaguchi, M., Okamoto, T., Yoneshima, Y., Tanaka, K., Okamoto, I., Tagawa, T. & Mori, M., 2月 2021, In: Lung Cancer. 152, p. 27-33 7 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Patient 100%
  • Non Small Cell Lung Cancer 83%
  • Immune Checkpoint Inhibitor 83%
  • Overall Survival 66%
  • Albumin 66%
  23 被引用数 (Scopus)

• Identification of SLC38A7 as a Prognostic Marker and Potential Therapeutic Target of Lung Squamous Cell Carcinoma

  Haratake, N., Hu, Q., Okamoto, T., Jogo, T., Toyokawa, G., Kinoshita, F., Takenaka, T., Tagawa, T., Iseda, N., Itoh, S., Yamada, Y., Oda, Y., Shimokawa, M., Kikutake, C., Suyama, M., Unoki, M., Sasaki, H. & Mori, M., 6月 18 2021, (印刷前の電子出版) In: Annals of surgery.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Oncogene 100%
  • Protein 75%
  • Overall Survival 75%
  • Nested Gene 50%
  • Messenger RNA 50%
  5 被引用数 (Scopus)

• Interleukin-38 promotes tumor growth through regulation of CD8⁺ tumor-infiltrating lymphocytes in lung cancer tumor microenvironment

  Kinoshita, F., Tagawa, T., Akamine, T., Takada, K., Yamada, Y., Oku, Y., Kosai, K., Ono, Y., Tanaka, K., Wakasu, S., Oba, T., Osoegawa, A., Shimokawa, M., Oda, Y., Hoshino, T. & Mori, M., 1月 2021, In: Cancer Immunology, Immunotherapy. 70, 1, p. 123-135 13 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Interleukin-38 100%
  • CD8 24%
  • Tumor Infiltrating Lymphocyte 18%
  • Tumor-Infiltrating Lymphocytes 18%
  • Tumor Progression 15%
  18 被引用数 (Scopus)

• Mutational signatures in squamous cell carcinoma of the lung

  Osoegawa, A., Takada, K., Okamoto, T., Sato, S., Nagahashi, M., Tagawa, T., Tsuchida, M., Oki, E., Okuda, S., Wakai, T. & Mori, M., 2月 2021, In: Journal of Thoracic Disease. 13, 2, p. 1075-1082 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Neoplasm 100%
  • Smoking 83%
  • Patient 66%
  • DNA Mismatch Repair 50%
  • Squamous Cell Lung Carcinoma 50%
  3 被引用数 (Scopus)

• Prognostic impact of albumin-bilirubin (ALBI) grade on non-small lung cell carcinoma: A propensity-score matched analysis

  Kinoshita, F., Yamashita, T., Oku, Y., Kosai, K., Ono, Y., Wakasu, S., Haratake, N., Toyokawa, G., Takenaka, T., Tagawa, T., Shimokawa, M., Nakashima, N. & Mori, M., 3月 2021, In: Anticancer research. 41, 3, p. 1621-1628 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Patient 100%
  • Albumin 90%
  • Bilirubin 90%
  • Non Small Cell Lung Cancer 50%
  • Cancer Specific Survival 30%
  5 被引用数 (Scopus)

• Prognostic Impact of Smoking Period in Patients with Surgically Resected Non-small Cell Lung Cancer

  Takamori, S., Shimokawa, M., Matsubara, T., Haratake, N., Toyozawa, R., Miura, N., Yamaguchi, M., Seto, T., Tagawa, T., Okamoto, T., Takenoyama, M., Maehara, Y. & Mori, M., 2月 2021, In: Annals of Surgical Oncology. 28, 2, p. 685-694 10 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Smoking 100%
  • Patient 66%
  • Non Small Cell Lung Cancer 44%
  • Pneumonectomy 33%
  • Lung Cancer 22%
  6 被引用数 (Scopus)

• The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance

  Haratake, N., Toyokawa, G., Seto, T., Tagawa, T., Okamoto, T., Yamazaki, K., Takeo, S. & Mori, M., 2021, In: Expert Review of Anticancer Therapy. 21, 9, p. 975-988 14 p.

  研究成果: ジャーナルへの寄稿 › 総説 › 査読

  • Anaplastic Lymphoma Kinase Inhibitor 100%
  • Anaplastic Lymphoma Kinase 66%
  • Non Small Cell Lung Cancer 33%
  • Clinical Trial 33%
  • Crizotinib 33%
  6 被引用数 (Scopus)
• 2020

  Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease-free survival in individuals with non-small cell lung cancer

  Ando, N., Tanaka, K., Otsubo, K., Toyokawa, G., Ikematsu, Y., Ide, M., Yoneshima, Y., Iwama, E., Inoue, H., Ijichi, K., Tagawa, T., Nakanishi, Y. & Okamoto, I., 10月 1 2020, In: Thoracic Cancer. 11, 10, p. 2830-2839 10 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Phosphotransferase Activator 100%
  • Non Small Cell Lung Cancer 41%
  • Disease Free Survival 33%
  • Specimen 25%
  • In Vitro 25%
  2 被引用数 (Scopus)

• Ciliated muconodular papillary tumor of the lung: a case report and literature review

  Abe, M., Osoegawa, A., Miyawaki, M., Noda, D., Karashima, T., Takumi, Y., Hashimoto, T., Okamoto, T., Daa, T. & Sugio, K., 11月 1 2020, In: General thoracic and cardiovascular surgery. 68, 11, p. 1344-1349 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Papilloma 100%
  • Lung 42%
  • Neoplasm 28%
  • Case Report 28%
  • Cells 14%
  10 被引用数 (Scopus)

• Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors

  Takada, K., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Takamori, S., Toyokawa, G., Oba, T., Osoegawa, A., Tagawa, T., Oda, Y., Nakanishi, Y. & Mori, M., 5月 1 2020, In: Journal of Cancer Research and Clinical Oncology. 146, 5, p. 1217-1225 9 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Muscle 100%
  • Programmed Cell Death 57%
  • Skeletal Muscle 57%
  • Non Small Cell Lung Cancer 57%
  • Patient 28%
  33 被引用数 (Scopus)

• Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study

  Takada, K., Takamori, S., Matsubara, T., Haratake, N., Akamine, T., Kinoshita, F., Ono, Y., Wakasu, S., Tanaka, K., Oku, Y., Oba, T., Osoegawa, A., Tagawa, T., Takenoyama, M., Shimokawa, M., Oda, Y. & Mori, M., 11月 2020, In: PloS one. 15, 11 November, e0241580.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Lymphocyte 100%
  • Marker 70%
  • Monocyte 50%
  • Neutrophil 40%
  • Overall Survival 40%
  7 被引用数 (Scopus)

• Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma

  Kinoshita, F., Takada, K., Yamada, Y., Oku, Y., Kosai, K., Ono, Y., Tanaka, K., Wakasu, S., Oba, T., Osoegawa, A., Tagawa, T., Shimokawa, M., Oda, Y. & Mori, M., 6月 1 2020, In: Annals of Surgical Oncology. 27, 6, p. 2102-2109 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Lung Adenocarcinoma 100%
  • Tumor Infiltrating Lymphocyte 100%
  • Disease Free Survival 80%
  • Patient 60%
  • Programmed Cell Death 60%
  11 被引用数 (Scopus)

• Does short-term cessation of smoking before lung resections reduce the risk of complications?

  Takenaka, T., Shoji, F., Tagawa, T., Kinoshita, F., Haratake, N., Edagawa, M., Yamazaki, K., Takenoyama, M., Takeo, S. & Mori, M., 12月 2020, In: Journal of Thoracic Disease. 12, 12, p. 7127-7134 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Smoking 100%
  • Surgery 27%
  • Nicotine Withdrawal 27%
  • Patient 11%
  • Pneumonectomy 11%
  2 被引用数 (Scopus)

• Evaluating the platelet distribution width-to-plateletcrit ratio as a prognostic marker for patients with breast cancer

  Takeuchi, H., Noda, D., Abe, M., Anami, K., Miyawaki, M., Osoegawa, A. & Sugio, K., 7月 2020, In: Anticancer research. 40, 7, p. 3947-3952 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Platelet 100%
  • Patient 55%
  • Breast Cancer 33%
  • Neoplasm 22%
  • Biological Marker 22%
  4 被引用数 (Scopus)

• Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype

  Takada, K., Toyokawa, G., Kinoshita, F., Jogo, T., Kohashi, K., Wakasu, S., Ono, Y., Tanaka, K., Oba, T., Osoegawa, A., Tagawa, T., Azuma, K., Okamoto, I., Shimokawa, M., Oda, Y. & Mori, M., 10月 1 2020, In: Journal of Cancer Research and Clinical Oncology. 146, 10, p. 2639-2650 12 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Programmed Cell Death 100%
  • Indoleamine 2,3 Dioxygenase 80%
  • Differentiation 70%
  • Tumor Infiltrating Lymphocyte 60%
  • Ligand 50%
  8 被引用数 (Scopus)

• LINE-1 Hypomethylation is associated with malignant traits and cell proliferation in lung adenocarcinoma

  Kitahara, H., Okamoto, T., Shimamatsu, S., Kohno, M., Morodomi, Y., Tagawa, T., Kitao, H., Okano, S., Oda, Y., Maehara, Y. & Mori, M., 10月 2020, In: Anticancer research. 40, 10, p. 5659-5666 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Long Interspersed Nuclear Element 100%
  • Methylation 40%
  • Mutation 20%
  • Gene Mutation 10%
  • Immunoreactivity 10%
  3 被引用数 (Scopus)

• LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma

  Kitahara, H., Okamoto, T., Shimamatsu, S., Kohno, M., Morodomi, Y., Tagawa, T., Kitao, H., Okano, S., Oda, Y., Maehara, Y. & Mori, M., 10月 2020, In: Anticancer research. 40, 10, p. 5659-5666 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Long Interspersed Nuclear Element 100%
  • Methylation 40%
  • Mutation 20%
  • Gene Mutation 10%
  • Immunoreactivity 10%

• NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration

  Ikematsu, Y., Tanaka, K., Toyokawa, G., Ijichi, K., Ando, N., Yoneshima, Y., Iwama, E., Inoue, H., Tagawa, T., Nakanishi, Y. & Okamoto, I., 8月 2020, In: Lung Cancer. 146, p. 97-104 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Small Cell Lung Cancer 100%
  • Diseases 46%
  • Patient 23%
  • Neoplasm 23%
  • Lung Cancer Cell Line 23%
  10 被引用数 (Scopus)

• Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis

  Otsubo, K., Iwama, E., Ijichi, K., Kubo, N., Yoneshima, Y., Inoue, H., Tanaka, K., Osoegawa, A., Tagawa, T., Nakanishi, Y. & Okamoto, I., 7月 1 2020, In: Cancer Science. 111, 7, p. 2482-2487 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Idiopathic Pulmonary Fibrosis 100%
  • Neoplasm 38%
  • Lung Cancer 38%
  • Somatics 38%
  • Tissues 30%
  8 被引用数 (Scopus)

• Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy

  Takamori, S., Takada, K., Shimokawa, M., Matsubara, T., Haratake, N., Miura, N., Toyozawa, R., Yamaguchi, M., Takenoyama, M., Yoneshima, Y., Tanaka, K., Okamoto, I., Tagawa, T. & Mori, M., 10月 15 2020, In: International Journal of Cancer. 147, 8, p. 2327-2334 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Patient 100%
  • Lung Cancer 57%
  • Cells 57%
  • Programmed Cell Death 35%
  • Combination Therapy 28%
  3 被引用数 (Scopus)

• Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer

  Takamori, S., Tagawa, T., Toyokawa, G., Shimokawa, M., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Hirai, F., Honda, H. & Maehara, Y., 3月 2020, In: Annals of Thoracic Surgery. 109, 3, p. 914-920 7 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Skeletal Muscle 100%
  • Patient 54%
  • Non Small Cell Lung Cancer 45%
  • Surgery 18%
  • Prognosis 9%
  14 被引用数 (Scopus)

• Rapidly destructive coxarthrosis as a potential side effect of crizotinib in a patient with ROS1-positive lung adenocarcinoma

  Takamori, S., Seto, T., Jinnouchi, M., Oba, T., Yamaguchi, M. & Takenoyama, M., 2020, In: Therapeutics and Clinical Risk Management. 16, p. 17-20 4 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Patient 100%
  • Crizotinib 62%
  • Hip Osteoarthritis 50%
  • Oncogene 37%
  • Lung Adenocarcinoma 37%
  2 被引用数 (Scopus)

• Relationship between obstructive lung disease and non-small cell lung cancer

  Akamine, T., Tagawa, T. & Mori, M., 3月 1 2020, In: Journal of Thoracic Disease. 12, 3, p. 1145-1146 2 p.

  研究成果: ジャーナルへの寄稿 › レター › 査読

  Open Access

• Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy

  Takada, K., Takamori, S., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Oba, T., Osoegawa, A., Tagawa, T., Takenoyama, M., Oda, Y., Nakanishi, Y. & Mori, M., 7月 2020, In: Lung Cancer. 145, p. 18-26 9 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Patient 100%
  • Lymphocyte 100%
  • Marker 80%
  • Programmed Cell Death 80%
  • Neutrophil 80%
  44 被引用数 (Scopus)
• 2019

  ¹⁸F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer

  Takada, K., Toyokawa, G., Yoneshima, Y., Tanaka, K., Okamoto, I., Shimokawa, M., Wakasu, S., Haro, A., Osoegawa, A., Tagawa, T., Oda, Y., Nakanishi, Y. & Mori, M., 12月 1 2019, In: Scientific reports. 9, 1, 13362.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Positron Emission Tomography-Computed Tomography 100%
  • Programmed Cell Death 1 100%
  • Antibody 75%
  • Electric Potential 50%
  • Association 25%
  32 被引用数 (Scopus)

• A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma

  Matsubara, T., Takada, K., Azuma, K., Takamori, S., Toyokawa, G., Haro, A., Osoegawa, A., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., 6月 15 2019, In: Annals of Surgical Oncology. 26, 6, p. 1925-1933 9 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Squamous Cell Lung Carcinoma 100%
  • Programmed Death 1 Ligand 1 100%
  • Patient 66%
  • Programmed Cell Death 50%
  • Immunotherapy 50%
  22 被引用数 (Scopus)

• A novel prognostic marker in patients with non-small cell lung cancer: Musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase

  Takamori, S., Toyokawa, G., Shimokawa, M., Kinoshita, F., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Hirai, F., Tagawa, T., Oda, Y. & Maehara, Y., 2019, In: Journal of Thoracic Disease. 11, 3, p. 927-935 9 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Nutritional Status 100%
  • Creatine Kinase 85%
  • Non Small Cell Lung Cancer 71%
  • Skeletal Muscle 57%
  • Inpatient 42%
  12 被引用数 (Scopus)

• A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas

  Toyokawa, G., Takada, K., Tagawa, T., Hamamoto, R., Yamada, Y., Shimokawa, M., Oda, Y. & Maehara, Y., 2月 2019, In: Annals of Thoracic Surgery. 107, 2, p. 393-400 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Transcription Factor EZH2 100%
  • Programmed Death 1 Ligand 1 71%
  • Patient 35%
  • Lung Adenocarcinoma 35%
  • Association 21%
  17 被引用数 (Scopus)

• Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma

  Takada, K., Shimokawa, M., Tanaka, K., Kohashi, K., Haro, A., Osoegawa, A., Tagawa, T., Azuma, K., Okamoto, I., Oda, Y. & Mori, M., 6月 2019, In: PloS one. 14, 6, e0217991.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Indoleamine 2,3 Dioxygenase 100%
  • Indoleamine 2,3-dioxygenase 100%
  • Marker 83%
  • Programmed Cell Death 83%
  • Ligand 83%
  4 被引用数 (Scopus)

• Association of Low Body Mass Index with Poor Clinical Outcomes after Resection of Non-small Cell Lung Cancer

  Takada, K., Shimokawa, M., Akamine, T., Ono, Y., Haro, A., Osoegawa, A., Tagawa, T. & Mori, M., 4月 2019, In: Anticancer research. 39, 4, p. 1987-1996 10 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Non Small Cell Lung Cancer 100%
  • Body Mass Index 100%
  • Body Mass 100%
  • Patient 62%
  • Inpatient 50%
  11 被引用数 (Scopus)

• Clinical and Prognostic Significance of the Epithelial–Mesenchymal Transition in Stage IA Lung Adenocarcinoma: A Propensity Score–Matched Analysis

  Matsubara, T., Tagawa, T., Takada, K., Toyokawa, G., Shimokawa, M., Kozuma, Y., Akamine, T., Haro, A., Osoegawa, A. & Mori, M., 7月 2019, In: Clinical Lung Cancer. 20, 4, p. e504-e513

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Patient 100%
  • Lung Adenocarcinoma 37%
  • Cells 18%
  • Neoplasm 18%
  • Uvomorulin 18%
  10 被引用数 (Scopus)

• Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy

  Takada, K., Kohashi, K., Shimokawa, M., Haro, A., Osoegawa, A., Tagawa, T., Seto, T., Oda, Y. & Maehara, Y., 2月 2019, In: Lung Cancer. 128, p. 26-32 7 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Indoleamine 2,3 Dioxygenase 100%
  • Indoleamine 2,3-dioxygenase 100%
  • Programmed Cell Death 60%
  • Ligand 53%
  • Apoptosis 53%
  20 被引用数 (Scopus)

• First Case of a Primary Lung Granulosa Cell Tumor With a Mutation in the Forkhead Box L2 Gene

  Izuwa, A., Toyokawa, G., Shoji, F., Yamazaki, K., Momosaki, S., Furuya, K., Yamada, Y., Oda, Y. & Takeo, S., 5月 2019, In: Journal of Thoracic Oncology. 14, 5, p. e100-e102

  研究成果: ジャーナルへの寄稿 › レター › 査読

• HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome

  Takamori, S., Shoji, F., Okamoto, T., Kozuma, Y., Matsubara, T., Haratake, N., Akamine, T., Katsura, M., Takada, K., Toyokawa, G., Tagawa, T. & Maehara, Y., 4月 2019, In: Transplant Immunology. 53, p. 13-20 8 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Interferon 100%
  • Allograft 100%
  • Interleukin 10 100%
  • Syndrome 75%
  • Bronchiolitis Obliterans 75%
  1 被引用数 (Scopus)

• Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor

  Hino, T., Kamitani, T., Sagiyama, K., Yamasaki, Y., Okamoto, I., Tagawa, T., Ijichi, K., Yamamoto, H., Yabuuchi, H. & Honda, H., 2019, In: European Journal of Radiology Open. 6, p. 72-77 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Pleura Mesothelioma 100%
  • Neoplasm 20%
  • Differentiation 20%
  • Differential Diagnosis 20%
  • Mediastinum 20%

• Localized malignant pleural mesothelioma mimicking an anterior mediastinal tumor

  Hino, T., Kamitani, T., Sagiyama, K., Yamasaki, Y., Okamoto, I., Tagawa, T., Ijichi, K., Yamamoto, H., Yabuuchi, H. & Honda, H., 1月 1 2019, In: European Journal of Radiology Open. 6, p. 72-77 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Pleura Mesothelioma 100%
  • Neoplasm 20%
  • Differentiation 20%
  • Differential Diagnosis 20%
  • Mediastinum 20%
  9 被引用数 (Scopus)

• Lorlatinib for the treatment of patients with non-small cell lung cancer

  Akamine, T., Toyokawa, G., Tagawa, T., Yamazaki, K., Seto, T., Takeo, S. & Mori, M., 2月 2019, In: Drugs of Today. 55, 2, p. 107-116 10 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Anaplastic Lymphoma Kinase 100%
  • Protein Kinase C 33%
  • Non Small Cell Lung Cancer 33%
  • Drug 16%
  • Protein Tyrosine Kinase 16%
  3 被引用数 (Scopus)

• Prognosis of early-stage part-solid and pure-solid lung adenocarcinomas

  Kinoshita, F., Toyokawa, G., Matsubara, T., Kozuma, Y., Haratake, N., Takamori, S., Akamine, T., Hirai, F., Takenaka, T., Tagawa, T. & Maehara, Y., 5月 2019, In: Anticancer research. 39, 5, p. 2665-2670 6 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Neoplasm 100%
  • Prognosis 100%
  • Patient 66%
  • Disease Free Survival 66%
  • Ground Glass Opacity 66%
  9 被引用数 (Scopus)

• Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients

  Takamori, S., Takada, K., Azuma, K., Jogo, T., Shimokawa, M., Toyokawa, G., Hirai, F., Tagawa, T., Kawahara, A., Akiba, J., Okamoto, I., Nakanishi, Y., Oda, Y., Hoshino, T. & Maehara, Y., 6月 15 2019, In: Annals of Surgical Oncology. 26, 6, p. 1916-1924 9 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Patient 100%
  • Programmed Death 1 Ligand 1 75%
  • Lung Adenocarcinoma 37%
  • Biological Marker 25%
  • Overall Survival 25%
  20 被引用数 (Scopus)

• Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab

  Oba, T., Takamori, S., Toyozawa, R., Nosaki, K., Umeyama, Y., Haratake, N., Miura, N., Yamaguchi, M., Taguchi, K., Seto, T., Shimokawa, M. & Takenoyama, M., 9月 1 2019, In: Journal of Thoracic Disease. 11, 9, p. 3757-3768 12 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Nutritional Status 100%
  • Patient 50%
  • Non Small Cell Lung Cancer 50%
  • Pembrolizumab 42%
  • Therapeutic Procedure 28%
  27 被引用数 (Scopus)

• Pulmonary metastasis presenting as a ground glass opacity-like lesion with a thin-walled cavity: A case report

  Haro, A., Wakasu, S., Takada, K., Osoegawa, A., Kamitani, T., Tagawa, T. & Mori, M., 2019, In: International Journal of Surgery Case Reports. 60, p. 287-290 4 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Lesion 100%
  • Ground Glass Opacity 100%
  • Lung Metastasis 83%
  • Lymph Node Metastasis 66%
  • Tongue Cancer 66%
  2 被引用数 (Scopus)

• Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients

  Haratake, N., Seto, T., Takamori, S., Toyozawa, R., Nosaki, K., Miura, N., Oba, T., Toyokawa, G., Taguchi, K., Yamaguchi, M., Shimokawa, M. & Takenoyama, M., 9月 1 2019, In: Thoracic Cancer. 10, 9, p. 1779-1787 9 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Anaplastic Lymphoma Kinase 100%
  • Tyrosine-Kinase Inhibitor 100%
  • Protein Tyrosine Kinase Inhibitor 100%
  • Patient 88%
  • Combination Therapy 55%
  5 被引用数 (Scopus)

• The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial–mesenchymal transition in resected lung adenocarcinoma

  Matsubara, T., Toyokawa, G., Takada, K., Kinoshita, F., Kozuma, Y., Akamine, T., Shimokawa, M., Haro, A., Osoegawa, A., Tagawa, T. & Mori, M., 5月 2019, In: PloS one. 14, 5, e0215103.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  Open Access

  • Transcription Factor EZH2 100%
  • Mesenchymal-Epithelial Transition 60%
  • Vimentin 33%
  • Association 26%
  • Disease Free Survival 20%
  8 被引用数 (Scopus)

• The evolution of surgical treatment for gastrointestinal cancers

  Maehara, Y., Soejima, Y., Yoshizumi, T., Kawahara, N., Oki, E., Saeki, H., Akahoshi, T., Ikegami, T., Yamashita, Y. I., Furuyama, T., Sugimachi, K., Harada, N., Tagawa, T., Harimoto, N., Itoh, S., Sonoda, H., Andou, K., Nakashima, Y., Nagao, Y., Yamashita, N., & 17 othersKasagi, Y., Yukaya, T., Kurihara, T., Tsutsumi, R., Takamori, S., Sasaki, S., Ikeda, T., Yonemitsu, Y., Fukuhara, T., Kitao, H., Iimori, M., Kataoka, Y., Wakasa, T., Suzuki, M., Teraishi, K., Yoshida, Y. & Mori, M., 11月 1 2019, In: International Journal of Clinical Oncology. 24, 11, p. 1333-1349 17 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Malignant Neoplasm 100%
  • Tissues 100%
  • Gastrointestinal Cancer 75%
  • Development 50%
  • Chromosomal Instability 50%
  5 被引用数 (Scopus)

• The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer

  Shimamatsu, S., Takenoyama, M., Shimokawa, M., Takada, K., Edagawa, M., Toyozawa, R., Nosaki, K., Oba, T., Tagawa, T., Yamaguchi, M., Taguchi, K. & Seto, T., 10月 2019, In: Annals of Thoracic Surgery. 108, 4, p. 1080-1086 7 p.

  研究成果: ジャーナルへの寄稿 › 学術誌 › 査読

  • Ground Glass Opacity 100%
  • Neoplasm 55%
  • Predictor 55%
  • Prognosis 22%
  • Time 22%
  6 被引用数 (Scopus)

• The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: A comparison with smokers

  Akamine, T., Tagawa, T., Shimokawa, M., Matsubara, T., Kozuma, Y., Haratake, N., Takamori, S., Toyokawa, G. & Maehara, Y., 5月 1 2019, In: Interactive cardiovascular and thoracic surgery. 28, 5, p. 735-743 9 p.

  研究成果: ジャーナルへの寄稿 › 総説 › 査読

  Open Access

  • Smoking 100%
  • Patient 50%
  • Non Small Cell Lung Cancer 43%
  • Obstructive Lung Disease 43%
  • Recurrence Free Survival 18%
  5 被引用数 (Scopus)